Ignore the noise in GLP-1 stocks. Find the best value instead.

Let's start with the background. Currently there are four branded and patent-protected GLP-1 weight-loss drugs on the market. Novo Nordisk owns two of them: Ozempic and Wegovy. Eli Lilly (NYSE ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...

“My background in biochemistry ... Working alongside a specialist diabetes dietitian at Novo Nordisk, he developed recipes that ticked every box: nutritious, affordable and, most importantly, ...

Q4 2024 Results Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsJustin Schreiber - Chairman and Chief ...